Drug Profile
Research programme: CNS small molecule modulators - Evotec SE/UCB
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; UCB
- Developer Evotec SE; UCB
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in Germany
- 07 Jul 2011 Early research in CNS disorders in Germany (unspecified route)